Safety and Efficacy of Combined Oral Contraceptive Ethinyl Estradiol/Drospirenone (YAZ) in Chinese Women: A Single-Arm, Open-Label, Multicenter, Post-Authorization Study
ConclusionThe 24/4 YAZ regimen showed good safety profile, contraceptive reliability, good cycle control along with subgroup of patients. Improvements in dysmenorrhea and acne were also observed. No events of venous thromboembolism/arterial thromboembolism were reported.Trial RegistrationClinicalTrials.gov identifier, NCT02710708; Center for Drug Evaluation (CDE), China Food and Drug Administration (CFDA) number: CTR20160203.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Acne | Bleeding | China Health | Drugs & Pharmacology | Estradiol | Pain | Pregnancy | Statistics | Study | Thrombosis | Women | Yasmin | Yaz